# FibroBiologics, Inc. (FBLG) — delisting/forced [announced]
Source: SEC API (secapi.ai) · situation sit_59f75c4fe834778c6f00 · retrieved 2026-08-11T16:12:47.400Z

## Overview
FibroBiologics, Inc. is a pharmaceutical company engaged in the development of biologic therapies; it is incorporated in Delaware and trades on The Nasdaq Capital Market under the ticker symbol FBLG.

On July 22, 2026, FibroBiologics, Inc. received a Staff Determination letter from Nasdaq notifying the company that its securities would be delisted from The Nasdaq Capital Market due to non-compliance with Nasdaq Listing Rule 5550(a)(2). The company's common stock bid price closed below $1.00 per share for 30 consecutive business days from June 8, 2026 through July 21, 2026. The company is ineligible for a standard 180-calendar day compliance period because it effected a reverse stock split within the prior one-year period. Unless the company requests an appeal by July 29, 2026, its securities will be suspended at the opening of business on July 31, 2026. The company intends to request a hearing before a Nasdaq Hearings Panel to appeal the determination.

## Terms
- Counterparty: The Nasdaq Stock Market LLC · Price/share: $1

## Key dates
- Announced 2026-07-24 · Expiry 2026-07-29

## Timeline
- 2026-07-24 · 8-K (0001193125-26-316067): 8-K - FibroBiologics, Inc. — *FibroBiologics, Inc. is a pharmaceutical company engaged in the development of biologic therapies; it is incorporated in Delaware and trades on The Nasdaq Capital Market under the ticker symbol FBLG.* On July 22, 2026, FibroBiologics, Inc. received a Staff Determination letter from Nasdaq notifying the company that its securities would be delisted from The Nasdaq Capital Market due to non-compliance with Nasdaq Listing Rule 5550(a)(2). The company's common stock bid price closed below $1.00 per share for 30 consecutive business days from June 8, 2026 through July 21, 2026. The company is ineligible for a standard 180-calendar day compliance period because it effected a reverse stock split within the prior one-year period. Unless the company requests an appeal by July 29, 2026, its securities will be suspended at the opening of business on July 31, 2026. The company intends to request a hearing before a Nasdaq Hearings Panel to appeal the determination.
  https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-316067.txt

## Citations
- 0001193125-26-316067 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526316067